|
|||||
|
|
Fixed-Dose Combination of Tafluprost and Timolol in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: Comparison with Other Fixed-Combination Products |
|
| Authors: | Gábor Holló Jouni Vuorinen Juhani Tuominen Teppo Huttunen Auli Ropo Norbert Pfeiffer |
| Affiliation: | 1. Department of Ophthalmology, Semmelweis University, Budapest, Hungary 2. Oy 4Pharma Ltd, Turku, Finland 3. Department of Mathematics and Statistics, University of Turku, Turku, Finland 4. Santen Oy, Clinical Research and Medical Affairs, Helsinki, Finland 5. Department of Ophthalmology, Mainz University Medical Center, Mainz, Germany |
| Abstract: | A new preservative-free fixed-dose combination of 0.0015% tafluprost, a prostaglandin F2α analog, and 0.5% timolol (TAF/TIM; Santen Oy, Tampere, Finland), a beta-adrenergic antagonist has recently been developed. The intraocular pressure (IOP) reduction with TAF/TIM in open-angle glaucoma and ocular hypertension is similar to that of other prostaglandin–timolol fixed-combination products. Patients with high IOP responded well to TAF/TIM with reductions of up to 40% (>13 mmHg) and beyond. Compared to previous controlled and double-masked clinical trials with DuoTrav® (Alcon, Fort Worth, USA) and Ganfort® (Allergan, Irvine, USA), TAF/TIM caused less superficial ocular side effects and less conjunctival hyperemia. Plausible explanations for the differences in side effects between the fixed-combination products are discussed. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |